Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Biochim Biophys Acta Mol Cell Biol Lipids. 2018 Aug 1;1863(10):1246–1256. doi: 10.1016/j.bbalip.2018.07.016

Fig. 2.

Fig. 2.

Recording and pharmacological inhibition of Panx1 channel activity in podocytes. Podocyte patches were held at −50 mV and polarized by 100 ms voltage pulses between −70 and 80 mV. A. Representative whole-cell currents of podocytes with or without CBX. B. I-V curves of steady-state currents recorded in podocytes with or without CBX (25 μM) (n=10 batches of experiments). C. Representative whole-cell currents of podocytes in the presence or the absence of PBNC. D. I-V curves of steady-state currents in podocytes in the absence or presence of PBNC (1 mM) (n=12 batches of experiments). E. I-V curves of steady-state currents in podocytes transfected with Panx1 CRISPR/cas9 KO plasmid in the absence or presence of CBX (25 μM) (n=5 batches of experiments). F. Summarized data showing the steady-state currents at 80 mV in podocytes under different conditions. * p<0.05 vs. control (panel B and D) or Ctrl-Vehl (panel F). CBX, carbenoxolone; PBNC, probenecid; CRISPR KO, Panx1 CRISPR/cas9 KO plasmid.